-
Cytokine (KLT-1101)
Hematopoietic damage caused by tumor chemoradiationTumor immunotherapyPrevention and treatment of acute radiation diseases resulting from radiation -
Cell therapy drugs
Cell therapy drugs (CAR-T) used to treat hematological or solid tumors -
Antibody biological drugs
Tumor immunotherapy drugsTumor targeted therapy drugsDrugs for the treatment of autoimmune diseases
Expert comment
The research results of KLT-1101 in stimulating bone marrow hematopoiesis, protecting the hematopoietic microenvironment, and radiation protection were highly evaluated in "Biotechnological Drug Research and Development and Quality Control (3rd Edition)" edited by Academician Wang Junzhi published by Science Press. It is believed that the drug has positive effects on anti-infective immunity, anti-tumor, etc., and "will successfully develop into a new anti-cancer drug with important clinical application value."
Application fields
-
Stimulate the bone marrow hematopoietic system
Prevent and treat granulocytopenia and thrombocytopenia caused by chemoradiotherapy
-
Regulate cellular immunity
Proliferate and activate T cells and NK cells, and activate patient's own immune system
-
Inhibit the growth, spread and metastasis of tumor cells
Treat various malignant tumor diseases
National defense security
The results of a joint study between KLT Pharmaceuticals and the Academy of Military Medical Sciences, P.L.A. China show that KLT-1101 can significantly improve the survival rate of primates within 24 hours after nuclear radiation exposure and without subsequent medical support. This product will greatly improve China's nuclear emergency drug reserve level, enhance the rescue efficiency of major nuclear accidents, increase the protection and handling capacity of public safety emergencies, and safeguard the peaceful development and utilization of atomic energy, which has great strategic significance for national defense security.